News

AddToAny

Google+ Facebook Twitter Twitter

COVID-19 anti-viral therapy

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19.

The study demonstrates the rapid process of isolating, testing and mass-producing antibody therapies against any infectious disease by using both genetically engineered mice and plasma from recovered COVID-19 patients.

The antibody cocktail evaluated by UMSOM researchers is being used to treat COVID-19 patients in a clinical trial that was launched in June.

To produce the monoclonal antibodies to fight COVID-19, the researchers needed to identify which antibodies fight the novel coronavirus most effectively.

This involved determining which could bind most effectively to the spike protein found on the surface of SARS-CoV-2. The team evaluated thousands of human antibodies from plasma donations from recovered COVID-19 patients. They also generated antibodies from mice genetically engineered to produce human antibodies when infected.  

bit.ly/2YPgTTD
 

Picture Credit | Science Photo Library

Related Articles

100 years of bacterial strains

Sarah Alexander and Ayuen Lual from the National Collection of Type Cultures look back over a century of providing authentic bacterial strains.

COVID tech news

Engineered llama antibodies

COVID 19: "More T cell data needed"

While early research on the adaptive immune response to COVID-19 primarily looked at antibodies, more information is now emerging on how T cells react to the SARS-CoV-2 virus – addressing a crucial knowledge gap.

Seven make the power list

This year, seven IBMS members were awarded places on The Pathologist’s power list.

Top